Join Protagonist Therapeutics for an in-person and virtual investor event providing key opinion leader (KOL) insights from Andrew Kuykendall, MD (Moffitt Cancer Center) and Joseph Michael Scandura, MD, PhD (Weill Cornell Medicine), who will discuss the unmet medical need and current treatment landscape for patients with the rare chronic blood disorder polycythemia vera (PV) in the context of the opportunity for rusfertide.

The event will review the Phase 2 PACIFIC data, the Phase 2 REVIVE data, and the rusfertide Phase 3 VERIFY study design, which is expected to read out in Q1 2025. In addition, company management will provide a brief snapshot of the commercial opportunity.

A live question and answer session will follow the formal presentations. An informal lunch will be provided from 12:00-1:00 PM ET for in-person attendees, with an opportunity to meet the participants.